| Document |
Document Title |
|
WO/2014/054053A1 |
The present disclosure relates to a series of spirocyclic compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates, hydrates, N-Oxides, Co crystals and formulations there...
|
|
WO/2014/044738A1 |
The present invention relates to benzoimidazole-carboxylic acid amide compounds of the formula I, in which R', R", R"', R1, R2, R3, R4, R5, R6 and Z are defined as indicated below. The compounds of the formula I are APJ receptor modulato...
|
|
WO/2014/045031A1 |
This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing...
|
|
WO/2014/026330A1 |
The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
|
|
WO/2014/014951A1 |
The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric di...
|
|
WO/2014/014962A1 |
The present invention provides compounds of the formula: (I) that are 5HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5HT3 receptor such as emesis, pain, drug addiction, neurode...
|
|
WO/2014/009447A1 |
Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, W, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein. Also disclosed are methods of maki...
|
|
WO/2014/005274A1 |
A formula I compound, a derivate thereof, a medicated salt thereof, and a hydrate or solvate thereof. A medicine composition of the formula I compound with pharmaceutically effective amount and a pharmaceutically acceptable carrier. Use ...
|
|
WO/2014/007144A1 |
A method for producing an alicyclic N-oxyl compound by oxidizing an alicyclic secondary amine with an oxidizing agent, said method being characterized in that an alicyclic secondary amine compound and an oxidizing agent such as sodium pe...
|
|
WO/2013/149136A1 |
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceu...
|
|
WO/2013/143510A1 |
The present invention relates to a preparation method of tiotropium bromide of formula II, comprising the following steps: a) preparation of the scopine ester of formula I by transesterification of methyl di(2thienyl)glycolate of formula...
|
|
WO/2013/135219A1 |
The invention relates to a preparation method of the scopine ester of di-(2- thienyl)glycolic acid of formula I. The scopine ester of formula I is an important intermediate in the synthesis of tiotropium bromide, the substance with the c...
|
|
WO/2013/122107A1 |
The present invention relates to: a compound represented by formula (1) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition which contains, as an active ingredient, the compound or a pharmaceutically acceptable sa...
|
|
WO/2013/117886A1 |
The present invention relates to a novel process for the preparation of tiotropium bromide there is provided a process for preparing tiotropium bromide comprising (i) reacting scopine oxalate with diethylamine in an inert solvent to form...
|
|
WO/2013/112622A1 |
This invention provides novel (1R,4R) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof, preferably in substantially enantiomerically enriched forms, intermediates thereto, and processes of their synthesis.
|
|
WO/2013/107434A2 |
The invention relates to new polymorphous forms of tiotropium iodide of formula I and a method of their preparation, wherein a dichloromethane/acetonitrile solvate of tiotropium iodide of formula V is crystallized from water. The solutio...
|
|
WO/2013/064919A9 |
Compounds of general formula (I): or a stereoisomer, tautomer, polymorph, hydrate, solvate, or a pharmaceutically acceptable salt thereof, wherein R is as defined herein, are useful for the treatment of diseases and conditions which are ...
|
|
WO/2013/090260A1 |
The invention relates to the design and synthesis of novel anabaseine-based compounds, which are useful in treating or preventing a wide variety of conditions, including nervous system diseases or disorders, such as, schizophrenia, Alzhe...
|
|
WO/2013/079040A1 |
Mixed solvate of propyleneglycol/ethanol solvate of tiotropium bromide of formula V contains ethanol in the range of 3,000 to 40,000 ppm and propyleneglycol in the range of 3,000 to 40,000 ppm. An additional solution provides a method of...
|
|
WO/2013/061977A1 |
The present invention pertains to the compound represented by formula (I) (in the formula: X1, X2, X3, X4, X5, R5, R6, R7, R8, n, p, q, ring A, and ring B have the same meaning as the definitions described in the description) or a pharma...
|
|
WO/2013/062027A1 |
The invention according to the present application provides a therapeutic or prophylactic agent for diseases including mood disorders, anxiety disorders, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eatin...
|
|
WO/2013/053051A1 |
The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inh...
|
|
WO/2013/055910A1 |
The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof,that are useful as single pharmaceutical agents or in combination with one or more additional pharm...
|
|
WO/2013/050929A1 |
The present invention relates to a novel manufacturing process of pharmaceutically active compound of Formula (I) used as a long-acting anticholinergic bronchodilator. Starting from oxalic acid derivative of Formula (III) the invention d...
|
|
WO/2013/046138A1 |
The present invention relates to a process for the preparation of scopine esters, as intermediates in the synthesis of tiotropium bromide. In particular, it relates to a transesterification process between scopine alcohol and an ester of...
|
|
WO/2013/045461A1 |
Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula (I), including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are use...
|
|
WO/2013/017585A1 |
The invention relates to a compound of formula Ia or Ib wherein R1 represents -CO2R3, -COR4or -R5, wherein R3 represents unsubstituted or substituted C1-C6 alkyl, R4 represents hydrogen, unsubstituted or substituted C1-C6 alkyl, and R5 r...
|
|
WO/2013/018929A1 |
The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases. The present invention relates to a compound represen...
|
|
WO/2013/016160A1 |
The present invention relates to certain Imidazopyrazine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of...
|
|
WO/2013/012827A1 |
The present invention provides compounds of Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators ...
|
|
WO/2012/175520A1 |
The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
|
|
WO/2012/168359A1 |
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations w...
|
|
WO/2012/152854A1 |
The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators ...
|
|
WO/2012/146724A2 |
The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of diseas...
|
|
WO/2012/143526A1 |
The present invention relates to a compound of general formula (I), where: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN' group...
|
|
WO/2012/118461A1 |
The present invention refers to a crystalline compound I comprising Tiotropium bromide (formula I) and water, characterized in that it has an FT-Raman spectrum comprising peaks at wavenumbers (expressed in ± 2 cm-1) of 3070, 3053, 2982,...
|
|
WO/2012/118460A1 |
The present invention refers to a crystalline compound comprising a mixture of a compound of formula (I ) (Tiotropium bromide) and propionic acid, or a hydrate thereof, wherein the molar ratio of the compound of formula I and the propion...
|
|
WO/2012/118462A1 |
The present invention relates to the crystalline substance comprising Tiotropium bromide and process that shall be used in production of the said substance.
|
|
WO/2012/108490A1 |
[Problem] To provide an excellent therapeutic or prophylactic agent for dementia, schizophrenia, and the like, which is based on a serotonin 5-HT5A receptor-modulating action. [Solution] The present invention was realized by discovering ...
|
|
WO/2012/103806A1 |
The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula (I), pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metab...
|
|
WO/2012/095781A1 |
The invention relates to acyl sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to ...
|
|
WO/2012/087519A1 |
The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions,...
|
|
WO/2012/082381A1 |
The present invention relates to compounds represented by the following Formulas (I) and (II). Ring-A of Formulas I and II can be, for example, an aryl group, and Q' and Q''' can each be independently selected from groups, such as, halog...
|
|
WO/2012/069275A1 |
The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.
|
|
WO/2012/055018A1 |
Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atro...
|
|
WO/2012/053606A1 |
Provided is a compound useful as an inhibitor of the kinase activity of an EML4-ALK fusion protein or the like. The present inventors have made intensive studies on compounds useful for the treatment of cancer. Consequently, it is found ...
|
|
WO/2012/050315A2 |
The present invention relates to an azetidinium salt of an N-(3-sufonyloxypropyl)-2-β-carbomethoxy-3-β-(4-iodophenyl)
trophan compound, a selective method for preparing same and application thereof, and more particularly, provides a me...
|
|
WO/2012/043791A1 |
The present invention provides a 1,2,4-triazolone derivative represented by general formula (1A), which acts as an arginine vasopressin 1b receptor antagonist; a pharmacologically acceptable salt thereof; and a drug containing the same a...
|
|
WO/2012/035023A1 |
The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such de...
|
|
WO/2012/036276A1 |
The purpose of the present invention is to provide a novel compound or a pharmaceutically acceptable salt thereof useful in the prophylaxis or the treatment of diseases/disorders, such as schizophrenia, Alzheimer's disease, cognitive dys...
|
